... chronic myeloid leukemia (CML) patients who switched from Glivec ® (imatinib)* due to intolerance, resistance or physician ... had not achieved and sustained this response previously with Glivec[1],[2]. Results of this post-hoc analysis were presented today in an ...

... medicines for infectious diseases such as leprosy.
The Glivec International Patient Assistance Program
Recognizing from the ... success.
In 2002, Novartis Oncology introduced the Glivec® International Patient Assistance Program (GIPAP™), providing ...

... Novartis.
Full donation of certain products.
The Glivec International Patient Assistance Program
Recognizing from the ... success.
In 2002, Novartis Oncology introduced the Glivec International Patient Assistance Program (GIPAP TM ), providing ...

... 57.9% of eligible patients who had switched to Tasigna from Glivec ® maintaining TFR for 48 weeks after treatment cessation[2] ... both in the first-line setting and after switching from Glivec (imatinib)*[1],[2]. Discussions with regulatory authorities are underway ...

... in both the first-line setting and after switching from Glivec ®
Addition of TFR data to label provides patients and ... in both in the first-line setting and after switching from Glivec ® (imatinib)*[2],[3]. No new major safety findings were observed in ...

... or intolerant to at least one prior therapy, including Glivec® (imatinib)*, and in more than 110 countries for the treatment of adult ... with resistance or intolerance to prior therapy including Glivec and for the treatment of pediatric patients with newly diagnosed Ph+ CML ...

CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, ... to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), one of the most ...